FDA Seeks Input On GI Drug Bioequivalence Standards From Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will also offer a revised bio-inequivalence proposal at an Oct. 20 Pharmaceutical Science Advisory Committee meeting. On Oct. 19, the committee will discuss FDA's Critical Path initiative, risk-based GMP progress and parametric interval testing.
You may also be interested in...
FDA Science Board Will Look At “Future Plans” For “Critical Path” At Nov. 5 Meeting
The meeting is one of several by the agency to discuss the drug development initiative. The final report of FDA’s good manufacturing practices initiative will also be reviewed.
FDA Science Board Will Look At “Future Plans” For “Critical Path” At Nov. 5 Meeting
The meeting is one of several by the agency to discuss the drug development initiative. The final report of FDA’s good manufacturing practices initiative will also be reviewed.
GMP Oversight To Get FDA-Wide Coordination Under New Cmte.
The Council on Pharmaceutical Quality will oversee implementation of the initiative, which covers aseptic processing, quality systems, computerized systems in clinical trials, process analytical technologies and combination products.